Cell cycle analysis of Waldenström's macroglobulinemia

Clinical Lymphoma

Volumn 5, Issue 4, 2005, Pages 250-252

  Ocio, Enrique M ^a   Mateo, Gema ^a,b   Vidriales, Belén ^a   López Berges, M Consuelo ^a   García Sanz, Ramón ^a   Hernández, Jesús M ^a,b   Orfao, Alberto ^b,c   San Miguel, Jesús F ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

DNA cell content; DNA ploidy; Flow cytometry; IgM monoclonal gammopathy

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD38 ANTIGEN; IMMUNOGLOBULIN M; PROPIDIUM IODIDE; SYNDECAN 1;

ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CLINICAL ARTICLE; DIPLOIDY; DNA CONTENT; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MONOCLONAL IMMUNOGLOBULINEMIA; PLASMA CELL; TUMOR CELL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 18144373483     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.009     Document Type: Article

References (12)

1. Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.
2. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998; 82:1078-1081.
3. Almeida J, Orfao A, Mateo G, et al. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathol Biol (Paris) 1999; 47:119-127.
4. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152:1655-1665.
5. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol 1995; 8:735-759.
6. Tienhaara A, Pelliniemi TT. Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am J Clin Pathol 1992; 97:322-330.
7. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1995; 90:106-112.
8. Gutierrez NC, Hernandez JM, Garcia JL, et al. Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells. Haematologica 2000; 85:1146-1152.
9. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85:448-455.
10. Owen RG, Treon SP, Al Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-115.
11. Orfao A, Garcia-Sanz R, Lopez-Berges MC, et al. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994; 17:332-339.
12. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. DNA cell content studies in multiple myeloma. Leuk Lymphoma 1996; 23:33-41.